Generic placeholder image

Cardiovascular & Hematological Disorders-Drug Targets

Editor-in-Chief

ISSN (Print): 1871-529X
ISSN (Online): 2212-4063

Case Report

Post-Discharge Prophylactic Anticoagulation in COVID-19 Patients: A Clinical Dilemma

Author(s): Prakrati Yadav, Deepak Kumar*, Durga S. Meena, Naresh K, Midha, Gopal K. Bohra, Mahendra K. Garg and Abhishek H.L. Purohit

Volume 21, Issue 3, 2021

Published on: 14 September, 2021

Page: [206 - 209] Pages: 4

DOI: 10.2174/1871529X21666210914113752

Price: $65

conference banner
Abstract

Background: COVID-19 pandemic has taken a great toll on the health care system worldwide. Along with the pandemic, there is also a concern regarding post COVID-19 complications in recovered patients. Thromboembolism (TE) has been reported as a fatal complication in recovered patients with COVID-19. There is still a great dilemma in post-discharge TE prophylaxis and its long-term benefits.

Case Description: We reported three cases of post COVID-19 with complications related to both diseases as well as post discharge anticoagulant therapy. The first case is about a 60-yr-old male who developed Covid-19 pneumonia (moderate disease) and was discharged on rivaroxaban after initial improvement. 3 weeks later, the patient was readmitted with lower gastro-intestinal bleeding. The other two cases developed pulmonary thromboembolism within a span of 2-3 months (after recovered from COVID-19 pneumonia). Both these patients were not prescribed anticoagulants for TE prophylaxis.

Conclusion: There is an imperative need for effective guidelines for post discharge TE prophylaxis in COVID-19.

« Previous
Graphical Abstract

[1]
Aryal, M.R.; Gosain, R.; Donato, A.; Pathak, R.; Bhatt, V.R.; Katel, A.; Kouides, P. Venous thromboembolism in covid-19: towards an ideal approach to thromboprophylaxis, screening, and treatment. Curr. Cardiol. Rep., 2020, 22(7), 52-52.
[http://dx.doi.org/10.1007/s11886-020-01327-9] [PMID: 32529517]
[2]
Anderson, F.A., Jr; Spencer, F.A. Risk factors for venous thromboembolism. Circulation, 2003, 107(23)(1), I9-I16.
[PMID: 12814980]
[3]
Porfidia, A.; Valeriani, E.; Pola, R.; Porreca, E.; Rutjes, A.W.S.; Di Nisio, M. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb. Res., 2020, 196(196), 67-74.
[http://dx.doi.org/10.1016/j.thromres.2020.08.020] [PMID: 32853978]
[4]
Patell, R.; Bogue, T.; Koshy, A.; Bindal, P.; Merrill, M.; Aird, W.C.; Bauer, K.A.; Zwicker, J.I. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood, 2020, 136(11), 1342-1346.
[http://dx.doi.org/10.1182/blood.2020007938] [PMID: 32766883]
[5]
Roberts, L.N.; Whyte, M.B.; Georgiou, L.; Giron, G.; Czuprynska, J.; Rea, C.; Vadher, B.; Patel, R.K.; Gee, E.; Arya, R. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood, 2020, 136(11), 1347-1350.
[http://dx.doi.org/10.1182/blood.2020008086] [PMID: 32746455]
[6]
Flaczyk, A.; Rosovsky, R.P.; Reed, C.T.; Bankhead-Kendall, B.K.; Bittner, E.A.; Chang, M.G. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. Crit. Care, 2020, 24(1), 559.
[http://dx.doi.org/10.1186/s13054-020-03273-y] [PMID: 32938471]
[7]
Gerotziafas, G.T.; Catalano, M.; Colgan, M.P.; Pecsvarady, Z.; Wautrecht, J.C.; Fazeli, B.; Olinic, D.M.; Farkas, K.; Elalamy, I.; Falanga, A.; Fareed, J.; Papageorgiou, C.; Arellano, R.S.; Agathagelou, P.; Antic, D.; Auad, L.; Banfic, L.; Bartolomew, J.R.; Benczur, B.; Bernardo, M.B.; Boccardo, F.; Cifkova, R.; Cosmi, B.; De Marchi, S.; Dimakakos, E.; Dimopoulos, M.A.; Dimitrov, G.; Durand-Zaleski, I.; Edmonds, M.; El Nazar, E.A.; Erer, D.; Esponda, O.L.; Gresele, P.; Gschwandtner, M.; Gu, Y.; Heinzmann, M.; Hamburg, N.M.; Hamadé, A.; Jatoi, N.A.; Karahan, O.; Karetova, D.; Karplus, T.; Klein-Weigel, P.; Kolossvary, E.; Kozak, M.; Lefkou, E.; Lessiani, G.; Liew, A.; Marcoccia, A.; Marshang, P.; Marakomichelakis, G.; Matuska, J.; Moraglia, L.; Pillon, S.; Poredos, P.; Prior, M.; Salvador, D.R.K.; Schlager, O.; Schernthaner, G.; Sieron, A.; Spaak, J.; Spyropoulos, A.; Sprynger, M.; Suput, D.; Stanek, A.; Stvrtinova, V.; Szuba, A.; Tafur, A.; Vandreden, P.; Vardas, P.E.; Vasic, D.; Vikkula, M.; Wennberg, P.; Zhai, Z. Guidance for the management of patients with vascular disease or cardiovascular risk factors and covid-19: Position paper from VAS-European independent foundation in angiology/vascular medicine. Thromb. Haemost., 2020, 120(12), 1597-1628.
[http://dx.doi.org/10.1055/s-0040-1715798] [PMID: 32920811]
[8]
Cohen, A.T.; Harrington, R.A.; Goldhaber, S.Z.; Hull, R.D.; Wiens, B.L.; Gold, A.; Hernandez, A.F.; Gibson, C.M. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N. Engl. J. Med., 2016, 375(6), 534-544.
[http://dx.doi.org/10.1056/NEJMoa1601747] [PMID: 27232649]
[9]
Hajra, A.; Mathai, S.V.; Ball, S.; Bandyopadhyay, D.; Veyseh, M.; Chakraborty, S.; Lavie, C.J.; Aronow, W.S. Management of thrombotic complications in covid-19: an update. Drugs, 2020, 80(15), 1553-1562.
[http://dx.doi.org/10.1007/s40265-020-01377-x] [PMID: 32803670]
[10]
Chen, B.; Jiang, C.; Han, B.; Guan, C.; Fang, G.; Yan, S.; Wang, K.; Liu, L.; Conlon, C.P.; Xie, R.; Song, R. High prevalence of occult thrombosis in cases of mild/moderate COVID-19. Int. J. Infect. Dis., 2021, 104, 77-82.
[http://dx.doi.org/10.1016/j.ijid.2020.12.042] [PMID: 33352324]
[11]
Fiorini, NB; Garagoli, F; Bustamante, RC; Pizarro, R Acute pulmonary embolism in a patient with mild COVID-19 symptoms: a case report. Eur. Heart. J. Case. Rep., 2021, 5(1), ytaa563.
[12]
Scicchitano, P.; Tucci, M.; Bellino, M.C.; Cortese, F.; Cecere, A.; De Palo, M. The impairment in kidney function in the oral anticoagulation era. A pathophysiological insight. Cardiovasc. Drugs Ther., 2020, 35(3), 505-519.
[http://dx.doi.org/10.1007/s10557-020-07004-x] [PMID: 32535717]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy